The phase I study demonstrated a significantly favorable ORR, PFS, and OS for non-G12C KRAS-mutant NSCLC patients treated with the combination therapy of trametinib plus anlotinib. This evidence concerns the gene KRAS and non-small cell lung carcinoma.